CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: A retrospective analysis

Journal of Chemotherapy

Volumn 21, Issue 6, 2009, Pages 673-680

  Tsavaris, N ^a   Kosmas, C ^b   Papadoniou, N ^a   Kopterides, P ^a   Tsigritis, K ^a   Dokou, A ^a   Sarantonis, J ^a   Skopelitis, H ^a   Tzivras, M ^a   Gennatas, K ^c   Polyzos, A ^d   Papastratis, G ^e   Karatzas, G ^d   Papalambros, A ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Chemotherapy; Pancreatic carcinoma; Prognostic factors; Surgery

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; JAUNDICE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; WEIGHT REDUCTION; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77649280747     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.6.673     Document Type: Article

References (32)

1. Takai S, Satoi S, Toyokawa H, Yangimoto H, Sugimoto N, Tsuji K, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 2003; 26: 243-249.
2. Takeuchi M, Kondo S, Sugiura H, Katoh H. Pre-operative predictors of short-term survival after pancreatic cancer resection. Hepato-Gasterenterology 1998; 45: 2399-2403.
3. Cady B, Jenkins RL, Steele GD, Lewis D, Stone MD, Mc-Dermott WV, et al. Surgical margin in hepatic resection for colorectal metastasis. A critical and improvable determinant of outcome. Ann Surg 1998; 227: 566-571.
4. Micke O, Bruns F, Schafer U, Kurowski R, Horst E, Willich N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003; 23: 835-840.
5. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417.
6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057.
7. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base Report on pancreatic cancer. Cancer 1995; 76: 1671-1677.
8. Reber HA, Gloor B. Radical pancreatectomy. Surg Oncol Clin North Am 1998; 7: 157-163.
9. Fong Y, Blumgart LH, Former JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995;222: 426-437.
10. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH.etal. Pancreaticoduodenectomy for pancreatic adenocarcinoma: prospective adjuvant chemoradiation improves survival: a prospective, single institution experience. Ann Surg 1997; 225: 621-636.
11. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
12. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625-631.
13. Magistrelli P, Antinori A, Crucitti A, Le Greca A, Masetti R, Coppola R, et al. Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2000; 74: 36-40.
14. Matsuno S, Egawa S, Shibuya K, Shimamura H, Sunamura M, Takeda K, et al. Pancreatic cancer: current status of treatment and survival of 16071 patients diagnosed from 1981 - 1996, using the Japanese National Pancreatic Cancer Database. IntJ Clin Oncol 2000; 5: 153-157.
15. Link KH, Gansauge F, Goerich J, Leder G, Rillinger N, Berger HG. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol 1997; 23: 409-414.
16. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-125.
17. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-937.
18. Miller AR, Robinson EK, Lee JE, Pisters PW, Chiao PJ, Lenzi RL, etal. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg Oncol Clin North Am 1998; 7: 183-197.
19. Cubiella J, Castells A, Fondevila C, Sans M, Sabater L, Navarro S, et al. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 1999; 94: 1271-1278.
20. lkeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001; 91: 490-495.
21. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
22. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
23. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993; 217: 430-438.
24. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, etal. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-733.
25. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993; 165: 68-73.
26. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
27. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. Histological typing of tumours of the exocrine pancreas (2nd edn.) WHO International Histological Classification of Tumours. Springer-Verlag: Berlin, 1996.
28. Sobin LH, Wittekind Ch, Eds. UICC TNM classification of malignant tumors. Fifth edition, John Wiley & Sons, Inc., New York, 1997.
29. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E. Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma 2003; 50: 383-387.
30. Safi F, Schlosser W, Falkenreck S, Beger HG. CA19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatomy 1996; 20: 155-161.
31. Bakkevold KE, Kambestad B. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results. Ann Surg 1993; 217: 356-368.
32. 0kusaka T, Shuichi O, Hideki U, Ikeda M, Shimada K, Yamamoto J, et al. Abdominal pain in patients with respectable pancreatic cancer with reference to clinopathologic findings. Pancreas 2001; 22: 279-284.